ArticleAnnals of medicine2026
Effect of transcutaneous auricular vagus nerve stimulation on postoperative gastrointestinal dysfunction in patients with gynecological abdominal or pelvic tumors: a study protocol for a prospective, single-center, randomized, controlled clinical trial.
Article in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPostoperative gastrointestinal dysfunction (POGD) commonly presents with nausea, vomiting, abdominal distension, delayed flatus or stool, and prolonged intolerance to oral intake. It can cause postoperative pain, delayed gastrointestinal motility, or intestinal obstruction requiring secondary surgery, imposing substantial physical, emotional, and economic burdens. Transcutaneous auricular vagus nerve stimulation (taVNS), a non-invasive brain-gut axis modulator, may promote postoperative gastrointestinal recovery. This study will assess the efficacy and safety of taVNS in reducing the incidence of POGD after gynecological abdominal or pelvic tumor surgery. METHODS AND ANALYSIS: This randomized, single-center, controlled trial will enroll 210 patients scheduled for gynecological abdominal or pelvic tumor surgery and randomly assign them 1:1 to taVNS or sham-taVNS (n = 105 each). The primary outcome is the incidence of POGD within three days after surgery, assessed by the Intake, Feeling nauseated, Emesis, Exam, and Duration of symptoms (I-FEED) scoring system. Secondary outcomes include time to first flatus, time to first bowel movement, incidence and severity of postoperative nausea and vomiting, time to first ambulation, time to first oral intake, incidence of postoperative delirium, and postoperative pain intensity. ETHICS AND DISSEMINATION: The Ethics Committee of Huzhou Central Hospital approved this study (approval no. 202503014-03). Findings will be disseminated at national anesthesiology conferences and published in peer-reviewed journals.
trial registrationChiCTR2500104412 (Chinese Clinical Trial Registry, http://www.chictr.org.cn; registered June 17, 2025).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.